Sage Journals: Discover world-class research

Abstract

Background:

Heart failure has high mortality and is linked to substantial burden for patients, carers and health care systems. Patients with chronic heart failure frequently experience recurrent hospitalisations peaking at the end of life, but most prefer to avoid hospital. The drivers of hospitalisations are not well understood.

Aim:

We aimed to synthesise the evidence on factors associated with all-cause and heart failure hospitalisations of patients with advanced chronic heart failure.

Design:

Systematic review of studies quantitatively evaluating factors associated with all-cause or heart failure hospitalisations in adult patients with advanced chronic heart failure.

Data sources:

Five electronic databases were searched from inception to September 2020. Additionally, searches for grey literature, citation searching and hand-searching were performed. We assessed the quality of individual studies using the QualSyst tool. Strength of evidence was determined weighing number, quality and consistency of studies. Findings are reported narratively as pooling was not deemed feasible.

Results:

In 54 articles, 68 individual, illness-level, service-level and environmental factors were identified. We found high/moderate strength evidence for specialist palliative or hospice care being associated with reduced risk of all-cause and heart failure hospitalisations, respectively. Based on high strength evidence, we further identified black/non-white ethnicity as a risk factor for all-cause hospitalisations.

Conclusion:

Efforts to integrate hospice and specialist palliative services into care may reduce avoidable hospitalisations in advanced heart failure. Inequalities in end-of-life care in terms of race/ethnicity should be addressed. Further research should investigate the causality of the relationships identified here.

Keywords

Terminal care ethnic groups heart failure hospitals palliative care cardiology

What is already known about the topic?

Patients with chronic heart failure experience frequent hospitalisations increasing at the end of life.

Hospitalisations of chronically ill patients lead to a disruption of the highly valued continuity of care, burdensome and unnecessary treatments and a significant risk of adverse events.

What this paper adds?

We found high/medium strength evidence that palliative or hospice care was associated lower risk of hospitalisation for all causes or heart failure.

Our systematic review provided high strength evidence that black/non-white ethnicity is a risk factor for all-cause hospitalisation.

Meaningful evidence could only be gathered for few factors leaving abundant room for further research, especially on personal and psychosocial factors.

Implications for practice, theory or policy?

Palliative and hospice care initiatives should target patients with advanced chronic heart failure to reduce unnecessary hospitalisations at the end of life.

This research draws attention to the at-risk group of black/non-white populations for hospitalisations in patients with heart failure and thus can raise awareness among health professionals and policy makers to address racial and ethnic minority disadvantages in end-of-life care.

Our findings could inform the development of supportive interventions for high-risk patients and may help service providers and policy makers allocate limited resources.

Background

Chronic heart failure is highly prevalent and a major cause of morbidity and mortality worldwide.¹ Heart failure represents the leading cause of hospitalisation for people over 65 and constitutes the leading disease in terms of health care costs in many countries.^2,3 The prognosis for heart failure remains poor. After diagnosis, approximately 50% of the patients die within 5 years^4,5 while mortality in advanced heart failure is even higher.

Heart failure patients in their last months of life are often highly symptomatic,^6,7 with unpredictable exacerbations of breathlessness that can be particularly challenging to manage in the community.⁸ Accordingly, hospitalisations are not only very common in chronic heart failure but peak towards the end of life.^9
–11 During the last 6 months of life, as many as 80% of patients with heart failure are hospitalised.¹²

Hospital admissions can represent a crisis intervention that results in improved patient-related outcomes.^13
–15 However, admissions also provoke a disruption in continuity of care, which is particularly important to patients with chronic conditions.^16,17 They may also involve intensive resource use, burdensome treatments, unnecessary interventions and expose patients to a considerable risk of hospital-acquired adverse events.^18
–20 International data show that whilst half of the patients who die from heart failure do so in hospital,²¹ most patients with terminal heart disease wish to be cared for and die at home or in an inpatient hospice.²²

Given the adverse outcomes of heart failure hospitalisations, guidelines, position papers and end-of-life care strategies all advocate for a reduction in hospital admissions for patients with refractory heart failure.^4,23
–26 In order to achieve this goal, it is imperative to first understand the determinants of hospital admissions in heart failure patients. Several studies have examined one or more factors associated with hospital admissions,^27
–31 but this body of evidence has never been synthesised. To address this gap, we aimed to systematically identify and synthesise factors associated with hospitalisations in people with advanced chronic heart failure.

Methods

Design and review question

This was a systematic review reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. The review question was: ‘what factors are associated with hospital admissions in patients with chronic heart failure approaching the end of life?’ The primary outcome measure was all-cause hospitalisations and the secondary outcome was heart failure hospitalisations, both assessed as numbers of hospitalisations, rate of hospitalisations, time spent in hospital, or time to first hospitalisation. The review was not registered and the protocol was not published in advance.

Eligibility criteria

We conducted a systematic literature review of studies that reported original data examining at least one factor associated with hospitalisations in patients with a diagnosis of advanced chronic heart failure (including heart failure with reduced left ventricular ejection fraction and heart failure with preserved ejection fraction). Experimental, quasi-experimental, as well as observational study designs were considered for inclusion. Case reports, case series, reviews and qualitative studies were excluded. Unpublished studies (i.e. conference abstracts, dissertations and presentations) were considered if they met the study design criteria.

In order to characterise the target population with advanced chronic heart failure and the associated limited life expectancy as well as possible, we applied complex eligibility criteria.

Inclusion Criteria: Participants in included studies needed to fulfil at least one of the following inclusion criteria:

(a) Marked limitation of physical activity with heart failure symptoms at rest or minimal exertion (NYHA class III or IV)

(b) Stage D according to ACC/AHA guideline (refractory symptoms at rest despite guideline-directed medical treatment or refractory heart failure requiring specialised interventions)

(c) receiving (specialist or generalist) palliative care or hospice care or deemed suitable for these services by the publication’s research team or treating physicians according to their own criteria (e.g. risk assessment by means of the Gold Standards Framework Prognostic Indicator Guidance)

(d) Estimation of a prognosis of less than a year (either by clinical assessment e.g. use of the surprise question or identification as being in their last year of life by retrospective analysis of data 1 year prior to death)

Exclusion Criteria: Meeting at least one of the following criteria led to exclusion of studies:

(A) Studies with patients with acute heart failure/decompensation of heart failure or early disease or hospitalised patients not meeting other inclusion criteria than (a)

(B) Studies on patients undergoing or anticipating specialised cardiological interventions or operations (such as mechanical circulatory assist devices, heart transplant, cardiac resynchronisation therapy)

(C) Studies evaluating specific medical interventions or disease-focused interventions (e.g. medication, therapeutic interventions such as pleurocentesis) or operations (e.g. mechanical circulatory assist devices, heart transplant etc.)

(D) Studies specifically excluding patients meeting markers of advanced disease (any inclusion criteria as defined above under (a–d))

(E) Studies with patients in mixed stages of chronic heart failure with less than 75% of patients meeting at least one inclusion criteria under (a–d))

Studies reporting on mixed populations in terms of disease or heart failure stage were included if the results of the subpopulation relevant to our review were reported separately.

For controlled trials, no specific comparator was required. However, to enhance accuracy of our results, we set preconditions for control groups. Studies that did not characterise comparison samples or used undefined matching criteria were excluded. Propensity-matched studies were included if matching criteria of the artificially constructed control group seemed reasonable with respect to eligibility criteria, for example a comparison between patients with chronic heart failure receiving specialist palliative care or standard care, with indications of equivalent disease severity. Before-and-after studies were only considered for analysis if baseline characteristics met eligibility criteria.

Search strategy and study selection process

We searched five electronic databases (MEDLINE, EMBASE, CINAHL, PsycINFO, Cochrane Library) from inception to October 2018 using a combination of title/abstract keywords and MESH-terms (see Supplemental Data). The search was updated in September 2020 resulting in a total search period from inception (Medline 1946, EMBASE 1974, CINAHL 1937, PsycInfo 1806, Cochrane Library 1996) to September 2020. We restricted the search to publications in English, French, Italian, German and Spanish. Additionally, searches for grey literature (opengrey, Dart Europe Etheses), and hand-searching of the references of included papers were performed. Finally, citation searching of included studies on Scopus was done (on April 28th 2021). Ongoing research was looked for using clinicaltrials.gov. Authors were contacted if eligibility criteria matched but reporting lacked essential information for inclusion. Two authors (A.Z. and A.P.) independently screened all titles and abstracts to select eligible studies. Full text was retrieved if any uncertainty about eligibility remained. Disagreements on inclusion between A.Z. and A.P. were resolved through discussions.

Data collection process

For each included study, detailed information was extracted using a standardised data form including first author, year of publication, country of origin, population characteristics, sample size, factors studied, statistical analysis, results, association with primary and secondary outcomes and quality score.

Quality assessment and strength of evidence

Quality of individual studies was assessed using the validated Standard Quality Assessment Criteria for Evaluating Primary Research Papers from a Variety of Fields (QualSyst) tool, which has been used effectively in similar systematic reviews evaluating factors associated with health care use.^32
–34 Double quality assessment was performed by a second author on a randomly selected subsample of 10% of all articles (six articles). Interrater agreement was high ranging between 81% and 95% (mean 89%, SD 0.05%), so a double quality assessment of all articles was not considered necessary.

Based on previously published methods,³³ three categories of quality were assigned to the papers according to the allocated summary outcome QualSyst scores (‘low quality’ <50%, ‘medium quality’ 50%–70% and ‘high quality’ ⩾70%).

Synthesis of results

We derived data on all-cause hospitalisations (primary outcome) and heart failure hospitalisations (secondary outcome) including numbers of hospitalisations, rate of hospitalisations, time spent in hospital, or time to first hospitalisation. Primarily, relative measures (e.g. relative risk, odds ratios or hazard ratios) or for continuous variables differences in means with their 95% confidence level and level of significance were extracted. A positive association for factors and outcomes was reported if there was a statistically significantly increased likelihood of hospitalisation (p < 0.05), a negative association if there was a statistically significantly decreased likelihood of hospitalisation (p < 0.05), and no association if there was no statistically significant effect (p ⩾ 0.05). Factors were merged if a combination was considered feasible (e.g. black and non-white race, BMI and weight, systolic blood pressure and mean arterial pressure).

All studies fulfilling eligibility criteria were included in the analysis. For each variable, strength of available evidence across all studies was graded using an algorithm based on Bone et al.³³ (Figure 1). To assess the overall strength of evidence, the number of studies, their QualSyst scores and the consistency of results across studies were considered. If the same number of studies was found for opposite directions of association, the association was deemed inconclusive. Due to heterogeneity of study populations, methodological differences and summary outcome measures pooling of results in terms of meta-analysis was not considered feasible and findings are presented narratively.

Figure 1.

Algorithm for grading the strength of evidence based on Bone et al.³³ adapted from Gomes and Higginson.³⁵ Quality of individual studies was assessed by the Qualsyst tool.³²

Results

Study selection

Through database searching, a total of 15,534 records were identified. Additional searches described in methods identified another 3786 records. After removal of duplicates and title/abstract screening, full text screening was performed on 664 articles. Three studies were identified by reference searching of included and relevant articles^27,36,37, one additional study was included from citation searching.³⁸ No relevant ongoing studies were identified. Finally, 54 articles were selected for inclusion. The selection process is displayed in the PRISMA flow chart shown in Figure 2.

Figure 2.

PRISMA flow chart of the study selection process.

Study characteristics

We included 54 publications reporting on 40 studies. All articles were published in English, 30 studies originating in North America, two in Asia (Israel and Hong Kong), five in Europe and three studies were international multicentre studies. There was a great diversity of sample sizes, ranging from 40 to 396,024 patients. After subtracting obvious population overlap, a total of 1,226,186 participants was included in our analysis. The proportion of women ranged from 0% to 61%. A wide variety of factors and their association with hospitalisations were assessed. The included variables were combined into 10 individual-level factors (nine sociodemographic and one personal factor), 39 illness-related factors, 11 service level factors and seven environmental factors. All-cause admissions were assessed in 41 records, heart failure hospitalisations in 28 records with follow-up periods ranging from 30 days to 4 years. An overview of all included studies can be found in the Supplemental Data.

Quality assessment

Overall, the quality of the studies was rated as high, with 46 of a total of 54 studies rated as high quality, achieving a summary score of 70% and higher, four studies rated between 50% and 70% (medium quality) and four studies were of low quality (below 50%).

Synthesis of results

After reviewing the results, we grouped 67 factors into (i) individual-level (socio-demographic and personal) factors (e.g. gender), (ii) illness-level factors (e.g. comorbidities), (iii) service-level factors (e.g. models of care) and (iv) environmental factors (e.g. geographical variations) to facilitate reporting. An overview of all identified factors, their associations with the primary and secondary outcome, and the strength of evidence is presented in Tables 1 to 4. Factors supported by moderate and high strength evidence are additionally summarised below.

Table 1.

Overview of individual-level (sociodemographic and personal) factors and evidence of their associations with all-cause and heart failure hospitalisations.

Factor	All-cause hospitalisations					Heart failure hospitalisations
	Findings of individual studies			Overall Association	Strength of evidence	Findings of individual studies			Overall Association	Strength of evidence
	A	Reference	Q	Overall Association	Strength of evidence	A	Reference	Q	Overall Association	Strength of evidence
Sociodemographic factors
Black/Non-white Race	+	Reed et al.³⁹	***	⇑	High			n/a
	+	Unroe et al.³¹	***
	+	Warraich et al.⁴⁰	***
	+	Russel et al.⁴¹	***
Younger age	+	Dunlay et al.⁴²	***	⇑	Moderate	=	Ahmed et al.⁴³	***	⇒	Low
	+	Warraich et al.⁴⁰	***			=	Reed et al.³⁹	***	⇒	Low
	+	Wiskar et al.⁴⁴	***
	+	Russel et al.⁴¹	***
	=	Ahmed et al.⁴³	***
	=	Reed et al.³⁹	***
Female Gender	=	Dunlay et al.⁴²	***	⇒	Moderate	=	Petrie et al.⁴⁵	***	⇒	Very low
	=	Reed et al.³⁹	***
	=	Warraich et al.⁴⁰	***
	=	Russel et al.⁴¹	***
	−	Lam et al.⁴⁶	***
	−	Boman et al.⁴⁷	***
	−	Van Spall⁴⁸	***
	+	Wiskar et al.⁴⁴	***
Marital status	+	Dunlay et al.⁴²	***	×	Low			n/a
Marital status	=	Russel et al.⁴¹	***	×	Low
Residence/Discharge to skilled nursing facility	+	Dunlay et al.⁴²	***	⇑	Low			n/a
Residence/Discharge to skilled nursing facility	+	Wiskar et al.⁴⁴	***	⇑	Low			n/a
Primary caregiver	–	MacKenzie and Hanlon⁴⁹	***	×	Low			n/a
Primary caregiver	=	Russel et al.⁴¹	***	×	Low			n/a
Education (high school degree/college degreep)	=	Warraich et al.⁴⁰	***	⇒	Very low			n/a
Health care proxy	=	Russel et al.⁴¹	***	⇒	Very low
Household income	=	Warraich et al.⁴⁰	***	⇒	Very low			n/a
Insurance coverage	+	Wiskar et al.⁴⁴	***	⇑	Very low			n/a
Personal factors
Do not resuscitate status	−	Wiskar et al.⁴⁴	***	⇓	Very low			n/a

Direction of association (A) found in individual studies indicated as + (significant positive association), − (significant negative association), = (no significant association). Number of stars indicating quality (Q): with *** = high quality (⩾ 70% QualSyst). Overall association is indicated as ⇑ (overall evidence for positive association), ⇒ (overall evidence for no significant association), ⇓ (overall evidence for negative association), x (inconclusive results).

Table 2.

Overview of Illness-related factors and evidence of their associations with all-cause and heart failure hospitalisations.

Factor	All-cause hospitalisations					Heart failure hospitalisations
	Findings of individual studies			Overall Association	Strength of evidence	Findings of individual studies			Overall Association	Strength of evidence
	A	Reference	Q	Overall Association	Strength of evidence	A	Reference	Q	Overall Association	Strength of evidence
Laboratory parameters
COPD/Asthma	=	Reed et al.³⁹	***	⇒	Moderate
	=	Warraich et al.⁴⁰	***					n/a
	+	Dunlay et al.⁴²	***
Diabetes	=	Dunlay et al.⁴²	***	⇒	Moderate	+	Blecker et al.⁵⁰	***	⇑	Moderate
	=	Warraich et al.⁴⁰	***			+	Domanski et al.⁵¹	***
	+	Blecker et al.⁵⁰	***			=	Petrie et al.⁴⁵	***
Renal dysfunction/ estimated GFR/CKD as comorbidity	=	Dunlay et al.⁴²	***	⇒	Moderate	=	Petrie et al.⁴⁵	***	⇒	Very low
	=	Warraich et al.⁴⁰	***
	+	Bernacki et al.⁵²	***
Anaemia	=	Boman et al.⁴⁷	***	⇒	Low			n/a
Anaemia	=	Warraich et al.⁴⁰	***	⇒	Low			n/a
Cerebrovascular disease	=	Dunlay et al.⁴²	***	⇒	Low			n/a
Cerebrovascular disease	=	Warraich et al.⁴⁰	***	⇒	Low			n/a
Dementia	=	Dunlay et al.⁴²	***	×	Low			n/a
Dementia	−	Madelaire et al.¹¹	***	×	Low			n/a
History of Coronary artery disease/ Prior Myocardial Infarction	=	Gheorghiade et al.⁵³	***	⇒	Low	=	Gheorghiade et al.⁵³	***	⇒	Very low
Malignancy	=	Dunlay et al.⁴²	***	×	Low			n/a
Malignancy	−	Madelaire et al.¹¹	***	×	Low			n/a
Peripheral vascular disease	+	Dunlay et al.⁴²	***	×	Low
	=	Warraich et al.⁴⁰	***					n/a
	−	Ahmed et al.⁵⁴	***
Atrial Fibrillation	=	Ahmed et al.⁵⁵	***	⇒	Very low	+	Ahmed et al.⁵⁵	***	⇑	Very low
Frailty	+	Madan et al.²⁹	***	⇑	Very low	+	Madan et al.²⁹	***	⇑	Very low
History of Coronary artery bypass graft	=	Gheorghiade et al.⁵³	***	⇒	Very low	=	Gheorghiade et al.⁵³	***	⇒	Very low
Systolic blood pression/Mean arterial pressure (per 10 mm Hg increase)	=	Desai et al.⁵⁶	***	⇒	Moderate	=	Petrie et al.⁴⁵	***	⇒	Low
	=	Reed et al.³⁹	***
	+	Warraich et al.⁴⁰	***
Heart rate	−	Warraich et al.⁴⁰	***	⇓	Very low	+	Böhm et al.^57,a	***	⇒	Moderate
						=	^{Böhm et al.57,b}	***
						=	Petrie et al.⁴⁵	***
Body Mass index/weight	=	Dunlay et al.⁴²	***	⇒	Very low	=	Haass et al.^58,c	***	⇒	Low
Body Mass index/weight					Very low	=	Petrie et al.⁴⁵	***	⇒	Low
High pulse pressure			n/a			−	Petrie et al.⁴⁵	***	⇓	Low
High pulse pressure			n/a			−	Shah et al.⁵⁹	***	⇓	Low
LVEF	=	Reed et al.³⁹	***	⇒	Low	=	Petrie et al.⁴⁵	***	⇒	Very low
LVEF	=	Warraich et al.⁴⁰	***	⇒	Low				⇒	Very low
Poor health status	+	DiGiulio et al.⁶⁰	***	×	Low			n/a
Poor health status	−	Russel et al.⁶¹	***	×	Low			n/a
6 min walking test	−	Shah et al.⁶²	***	⇓	Very low			n/a
Closeness to death	+	Levenson et al.⁷	**	⇑	Very low			n/a
Diagnosed as outpatients vs inpatients						+	Madelaire et al.¹¹	***	⇑	Very low
HF-hospitalisation in last 6 months			n/a			+	Kristensen et al.⁶³	***	⇑	Very low
ICD/cardiac resynchronisation at baseline vs no device +						+	Madelaire et al.¹¹	***	⇑	Very low
Ischaemic aetiology of heart failure	=	Warraich et al.⁴⁰	***	⇒	Very low			n/a
Left ventricular or systolic HF vs other HF diagnoses						+	Madelaire et al.¹¹	***	⇑	Very low
Mode of death (non-sudden-cardiac death)	+	Reed et al.³⁹	***	⇑	Very low			n/a
NYHA IV			n/a			+	Petrie et al.⁴⁵	***	⇒	Very low
Peak VO2, mL/kg/min	=	Reed et al.³⁹	***	⇒	Very low			n/a
Smoking	=	Warraich et al.⁴⁰	***		Very low			n/a
NT-proBNP				n/a		+	Kristensen et al.⁶³ d	***	⇑	Moderate
						+	Kristensen et al. ^{64 e}	***
						=	Miller et al.⁶⁵	**
Blood urea nitrogen level	=	Reed et al.³⁹	***	×	Low			n/a
Blood urea nitrogen level	−	Warraich et al.⁴⁰	***	×	Low			n/a
BNP			n/a			=	Miller et al.⁶⁵	**	⇒	Very low
Creatinine, mg/dL	=	Reed et al.³⁹	***	⇒	Very low			n/a
Haemoglobin	=	Boman et al.⁴⁷	***	⇒	Very low			n/a
Hyperlipidaemia	=	Warraich et al.⁴⁰	***	⇒	Very low			n/a
Hypokalaemia	=	Tsimploulis et al.⁶⁶	**	⇒	Very low	=	Tsimploulis et al.⁶⁶	**	⇒	Very low
Iron deficiency	=	Boman et al.⁴⁷	***	⇒	Very low			n/a
Sodium, mEq/L	=	Reed et al.³⁹	***	⇒	Very low			n/a

Direction of association (A) found in individual studies indicated as + (significant positive association), − (significant negative association), = (no significant association). Number of stars indicating quality (Q): with ** = medium quality (⩾ 50 < 70% QualSyst), *** = high quality (⩾ 70% QualSyst). Overall association is indicated as ⇑ (overall evidence for positive association), ⇒ (overall evidence for no significant association), ⇓ (overall evidence for negative association), x (inconclusive results).

Table 3.

Overview of service-related factors and evidence of their associations with all-cause and heart failure hospitalisations.

Factor	All-cause hospitalisations					Heart failure hospitalisations
	Findings of individual studies			Overall Association	Strength of evidence	Findings of individual studies			Overall Association	Strength of evidence
	A	Reference	Q	Overall Association	Strength of evidence	A	Reference	Q	Overall Association	Strength of evidence
Specialist palliative care intervention/ referral to specialist palliative care/ hospice enrolment	−	Blecker et al.⁶⁷	***	⇑	High	−	Blecker et al.⁶⁷	***	⇓	Moderate
	−	Cassel et al.⁶⁸	***			−	Kheirbek et al.⁶⁹	***
	−	Brännström et al.⁷⁰	***			−	Wiskar et al.⁴⁴	***
	−	Gelfman et al.⁷¹	***			−	Pattenden et al.³⁶	*
	−	Kheirbek et al.⁶⁹	***			+	Lipinski et al.⁷²	*
	−	Warraich et al.⁴⁰	***			=	Rogers et al.³⁰	***
	−	Wiskar et al.⁴⁴	***
	−	Yim et al.⁷³	***
	−	Wong et al.^74,a	***
	−	Pattenden et al.^36,b	*
	−	Lycett et al.^75,c	*
	=	Mentz et al.³⁷	***
	+	Chuang et al.⁷⁶	***
	+	Kheirbek et al.³⁸	***
Hospital characteristics	=	Jones et al.^77,d	***	⇒	Low			n/a
Hospital characteristics	=	Warraich et al.^40,e	***	⇒	Low			n/a
Advance Care Planning	+	Ashana et al.⁷⁸	***	⇑	Very low
Caregiver intervention	=	McMillan et al.⁷⁸	**	⇒	Very low			n/a
Discharge to hospice/home care (vs home)	+	Wiskar et al.⁴⁴	***	⇑	Very low			n/a
For profit hospice	+	MacKenzie and Hanlon⁴⁹	***	⇑	Very low			n/a
Hospice discharge home vs health care facility	+	Warraich et al.⁴⁰	***	⇑	Very low			n/a
Hospice referral source (other than hospital)	=	Russel et al.⁴¹		⇒	Very low
Multidisciplinary disease management programme	=	Kalter et al.²⁷	***	⇒	Very low			n/a
Primary Care visits			n/a			−	Kronman et al.²⁸	***	⇓	Very low
Primary payer source (medicare vs other insurance source)	=	Russel et al.⁴¹	***	⇒	Very low

Direction of association (A) found in individual studies indicated as + (significant positive association), − (significant negative association), = (no significant association). Number of stars indicating quality (Q): with * = low quality (< 50% QualSyst score), ** = medium quality (⩾ 50 < 70% QualSyst), *** = high quality (⩾ 70% QualSyst). Overall association is indicated as ⇑ (overall evidence for positive association), ⇒ (overall evidence for no significant association), ⇓ (overall evidence for negative association), x (inconclusive results).

4 weeks ‘=’, 12 weeks ‘−’

Admissions per patients ‘=/−’, patients admitted ‘−’

30d ‘−’, 1 y ‘=’

Veterans Affairs vs other hospitals

Bed size/teaching status

Table 4.

Overview of environmental factors and evidence of their associations with all-cause and heart failure hospitalisations.

Factor	All-cause hospitalisations					Heart failure hospitalisations
	Findings of individual studies			Overall Association	Strength of evidence	Findings of individual studies			Overall Association	Strength of evidence
	A	Reference	Q	Overall Association	Strength of evidence	A	Reference	Q	Overall Association	Strength of evidence
Time trend	=	Warraich et al.⁴⁰	***	⇒	Moderate	=	Unroe et al.¹²	***	⇒	Very low
	=	Unroe et al.¹²	***
	=	Curtis et al.^80,a	*
	−	Dunlay et al.⁴²	***
	−	Kaul et al.^81,b	***
Geographic variation
USA vs. Canada	+	Curtis et al.⁸⁰	*	⇑	Very low			n/a
USA & Canada vs. Eastern Europe & Russia			n/a			+	Kristensen et al.⁸²	***	⇒	Very low
Western Europe vs. Eastern Europe & Russia			n/a			=	Kristensen et al.⁸²	***	⇒	Very low
Latin America vs. Eastern Europe & Russia			n/a			=	Kristensen et al.⁸²	***	⇒	Very low
Geographic variation within USA	=	Warraich et al.⁴⁰	***	⇒	Very low			n/a
Rural location	=	Warraich et al.⁴⁰	***	⇒	Very low			n/a

Direction of association (A) found in individual studies indicated as + (significant positive association), − (significant negative association), = (no significant association). Number of stars indicating quality (Q): with * = low quality (< 50% QualSyst score), *** = high quality (⩾ 70% QualSyst). Overall association is indicated as ⇑ (overall evidence for positive association), ⇒ (overall evidence for no significant association), ⇓ (overall evidence for negative association), x (inconclusive results).

USA sample.

Same sample as Canadian sample in Curtis et al.⁸⁰

Individual-level factors (see Table 1)

We found high strength evidence of an association between black or non-white race and all cause hospitalisations.^31,39
–41

There was moderate strength of evidence for an association between younger age and all-cause hospitalisations.^39
–44

Furthermore, we found moderate strength evidence for an equal risk of all-cause hospitalisations for both genders: there was with no significant association in four high quality studies^39
–42, three studies found a negative^46
–48, one high quality study found a positive association for women.⁴⁴

Illness-level factors

A wide range of illness-level factors (Table 2) including comorbidities, clinical variables and laboratory parameters were assessed, as shown in Table 3, however, few factors were significantly associated with all-cause or heart failure hospitalisations. There was a lack of consistent evidence, weakening the inferences that could be drawn.

Service-level factors

Nevertheless, we identified moderate strength evidence that none of chronic obstructive pulmonary disease (COPD), asthma, diabetes, renal failure or increased systolic blood pressure were associated with all-cause hospitalisations (Table 3).

In terms of the secondary outcome, there was moderate strength evidence supporting a positive association of diabetes with heart failure hospitalisations.^45,50,51 Furthermore, there was moderate strength evidence that higher heart rate was not associated with heart failure hospitalisations. Lastly, our review provided moderate strength that higher levels of NT-proBNP increased the risk of heart failure hospitalisations in advanced chronic heart failure.

We found high strength evidence that specialist palliative care interventions, referral to specialist palliative care and hospice enrolment are associated with a lower likelihood of all-cause hospitalisations. Eleven studies including nine high quality studies^{40,44,67
–71,73,79}, two low quality studies^36,75 consistently reported a lower likelihood of all-cause hospitalisations in patients receiving these interventions. In contrast, two high quality studies found a higher likelihood of all-cause hospitalisation in the intervention group compared to propensity-matched controls.^38,76 Only one high quality study yielded no significant association between the factor and all-cause hospitalisation.³⁷ Heart failure hospitalisations were examined in six studies,^{30,36,44,67,69,72} which overall found moderately strong evidence of a lower likelihood in patients being provided with specialist palliative or hospice care compared to controls receiving usual care.

An overview of other service-level factors and their association with all-cause hospitalisations and heart failure hospitalisations is presented in Table 4.

Environmental factors

Environmental factors assessed in the included studies comprised time trends (changes of hospitalisations over the years) as well as geographic variations and are displayed in Table 4. Five studies^{12,40,42,80,81} examined time trends in different settings in North America providing moderate evidence for no association with all-cause hospitalisations.

Discussion

Our systematic review provides the first synthesis of the association of individual, illness-related, service-level and environmental factors with all-cause and heart failure hospitalisations in patients with advanced chronic heart failure. Our findings add to the understanding of the complexity of factors influencing hospitalisations in the population of advanced heart failure. However, two factors in particularly stood out offering compelling evidence: (i) specialist palliative and hospice care proved to be protective, while (ii) black or non-white ethnicity was found to be a risk factor for hospitalisation.

Specialist palliative care interventions were associated with a lower likelihood of all-cause hospitalisations and a reduced likelihood of heart failure hospitalisations in advanced chronic heart failure patients. These findings, supported by high, and moderate strength evidence respectively, build on research highlighting the effect of specialist palliative care for more heterogeneous samples of heart failure patients.^83
–85 Indeed, chronic heart failure patients often suffer from palliative care-related problems with substantially higher prevalence of needs in advanced NYHA stages.^86,87 For several years, scientific societies of palliative care and cardiology have, therefore, strongly recommended specialist palliative care for this population.^{4,24,88
–90} But there is still a great disparity of specialist palliative care provision in heart failure compared to cancer patients despite increasing recognition of positive effects on patient-reported outcomes – without impact on mortality.^83,84,91 Patients with advanced heart failure are significantly less likely to have clinicians discussing hospice with them,⁹² experience more frequent emergency department visits and hospitalisations after hospice enrolment than cancer patients and are admitted to hospice care closer to death.⁹³ In this context, a variety of barriers to specialist palliative care referrals of heart failure patients have been documented, including misconceptions and confusion around terminology, difficulties of accurate prognostication and uncertainties about referral triggers.^94,95 Our systematic review further reinforces the importance of specialist palliative and hospice care for patients with heart failure to reduce unnecessary hospitalisations at the end of life. The results encourage timely integration of specialist palliative care for patients with chronic heart failure and may inform service planning and allocation of resources. However, the effectiveness of well-defined models of palliative and hospice care for advanced heart failure patients need to be further examined in high-quality prospective multicentre studies in order to generate a better understanding of which service elements prevent hospitalisations. Furthermore, qualitative studies could add to a deeper understanding of the mechanisms.

On the level of individual factors, high-grade evidence demonstrated that black/non-white ethnicity is an independent risk factor for all-cause hospitalisations, a finding that aligns with previous evidence of associations of non-white ethnicity with health care use in general heart failure populations,^96,97 end-stage heart failure populations⁹⁸ as well as throughout other end-of-life care populations.^33,99
–101 Reasons for persisting ethnical disparities are multifaceted. Explanations have been sought in differences in comorbidities, cultural beliefs and treatment preferences, distrust of providers, poor access to health care services, lower referral to specialists and barriers to the use of specialist palliative care.^97,102 Recently, racial and ethnic minority disadvantage has been flagged as an issue in palliative care offering multiple reasons to explain this phenomenon.^103,104 In addition to the occurrence of implicit and explicit racism at the individual and systemic level, psychosocial determinants such as deprivation have been discussed as possible causes. Interestingly, however, a higher prevalence of non-oncological diseases among ethnic minorities has also been implicated to be potentially causal.¹⁰³ Existing evidence, indeed, substantiates significant differences of referral rates to specialist palliative and hospice care in non-white patients with heart failure.^31,105 Given specialist palliative care is associated with reduced hospitalisations in heart failure, disparities in terms of use of hospice and palliative care for black or non-white people with heart failure may partially explain the higher likelihood of hospitalisations in this population, though this is yet to be corroborated by prospective research. Our results may encourage health care providers to reflect their own biases and to focus on culturally sensitive communication and individualised care. Moreover, we hope to raise awareness of organisations and policy makers to address grievances at the structural level.

While there was strong evidence for the factors of ethnicity and hospice and specialist palliative care, most of the many factors examined in the included studies were of low or very low evidence leaving abundant room for further research. We need to explore more deeply the causality of the identified associations as well as the interplay of factors. Evidence gaps, particularly in relation to psychosocial and personal factors, including preferences, attitudes and understanding of illness, as well as the role of informal carers and the caregiving situation, should be an additional focus for future research.

Strengths and limitations

This systematic review provides a comprehensive overview of the evidence on factors associated with hospitalisations in heart failure patients approaching the end of life, identified and synthesised by rigorous methods. However, there are limitations on study and review level.

Heterogeneity in study designs and outcomes considered, including short-term and long-term outcomes may restrict generalisability of results. A statistical analysis with pooling of effect sizes was thus not possible. Defining advanced heart failure is particularly challenging and little evidence exists regarding criteria indicating end of life for this patient population. Although care was taken in establishing meaningful eligibility criteria, it is conceivable that prognosis for the overall population was incorrectly gauged, leading to an overestimation or underestimation of effects.

Due to the inclusion of studies using register data as well as subpopulations of wider studies there is a possibility of remaining population overlap carrying the risk of over- or underestimating effects.

Use of a language restriction might have introduced language bias possibly excluding data from regions other than North-America and Europe where most of the included studies originated. Therefore, applicability, especially to low- and middle-income countries, might have been limited due to diverse population structures and relevant differences in health care systems across the world.

Conclusion

This systematic review identifies that access to hospice and specialist palliative care is associated with fewer hospitalisations in advanced chronic heart failure. Furthermore, there is strong evidence for the association of black/non-white ethnicity with increased hospitalisations in this population. These findings could foster development of supportive interventions for high-risk patients and could also advise service providers and policy makers in allocating limited resources. In particular, hospice and specialist palliative services should be involved in the care of patients with advanced chronic heart failure to avoid unnecessary hospital admissions at the end of life. It is important to address the disadvantage of racial and ethnic minorities in end-of-life care and to deliver culturally sensitive care in advanced heart failure. Evidence for most factors was low or very low strength, indicating that we still do not understand the full picture of what drives hospital admissions in advanced heart failure. Further research should provide more evidence of factors and a deeper understanding of the causality of the associations found.

Supplemental Material

sj-pdf-1-pmj-10.1177_02692163221123422 – Supplemental material for Factors associated with hospitalisations of patients with chronic heart failure approaching the end of life: A systematic review

Supplemental material, sj-pdf-1-pmj-10.1177_02692163221123422 for Factors associated with hospitalisations of patients with chronic heart failure approaching the end of life: A systematic review by Aina R Zehnder, Anna J Pedrosa Carrasco and Simon N Etkind in Palliative Medicine

Supplemental Material

sj-pdf-2-pmj-10.1177_02692163221123422 – Supplemental material for Factors associated with hospitalisations of patients with chronic heart failure approaching the end of life: A systematic review

Supplemental material, sj-pdf-2-pmj-10.1177_02692163221123422 for Factors associated with hospitalisations of patients with chronic heart failure approaching the end of life: A systematic review by Aina R Zehnder, Anna J Pedrosa Carrasco and Simon N Etkind in Palliative Medicine

Footnotes

Authorship

A.Z., A.P. and S.E. conceptualised and designed the review, A.Z. and A.P. undertook the analysis and interpretation of data, and drafted the manuscript, S.E. revised the draft.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Aina R Zehnder

Anna J Pedrosa Carrasco

Supplemental material

Supplemental material for this article is available online.

References

Savarese

Lund

LH.

Global public health burden of heart failure. Card Fail Rev 2017; 3: 7–11.

Ambrosy

Fonarow

Butler

, et al. The global health and economic burden of hospitalizations for heart failure: Lessons Learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123–1133.

Alla

Zannad

Filippatos

Epidemiology of acute heart failure syndromes. Heart Fail Rev 2007; 12: 91–95.

Yancy

Jessup

Bozkurt

, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240–e327.

Roger

Weston

Redfield

, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292: 344–350.

Nordgren

Sörensen

Symptoms experienced in the last six months of life in patients with end-stage heart failure. Eur J Cardiovasc Nurs 2003; 2: 213–217.

Levenson

McCarthy

Lynn

, et al. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc 2000; 48: S101–S109.

Gysels

Higginson

IJ.

Caring for a person in advanced illness and suffering from breathlessness at home: threats and resources. Palliat Support Care 2009; 7: 153–162.

Russo

Gelijns

Stevenson

, et al. The cost of medical management in advanced heart failure during the final two years of life. J Card Fail 2008; 14: 651–658.

10.

Chun

Wijeysundera

, et al. Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circ Heart Fail 2012; 5: 414–421.

11.

Madelaire

Gustafsson

Kristensen

, et al. Burden and causes of hospital admissions in heart failure during the last year of life. JACC Heart Fail 2019; 7: 561–570.

12.

Unroe

Greiner

Hernandez

, et al. Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007. Arch Intern Med 2011; 171: 196–203.

13.

Moser

Yamokoski

Sun

, et al. Improvement in health-related quality of life after hospitalization predicts event-free survival in patients with advanced heart failure. J Card Fail 2009; 15: 763–769.

14.

Allen

Stevenson

Grady

, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 2012; 125: 1928–1952.

15.

Robinson

Gott

Gardiner

, et al. A qualitative study exploring the benefits of hospital admissions from the perspectives of patients with palliative care needs. Palliat Med 2015; 29: 703–710.

16.

Senot

Continuity of care and risk of readmission: an Investigation into the healthcare journey of heart failure patients. Prod Oper Manag 2019; 28: 2008–2030.

17.

Simmonds

Glogowska

McLachlan

, et al. Unplanned admissions and the organisational management of heart failure: a multicentre ethnographic, qualitative study. BMJ Open 2015; 5: e007522.

18.

Schwendimann

Blatter

Dhaini

, et al. The occurrence, types, consequences and preventability of in-hospital adverse events - a scoping review. BMC Health Serv Res 2018; 18: 521.

19.

Grossmann

Gratwohl

Musy

, et al. Describing adverse events in medical inpatients using the Global Trigger Tool. Swiss Med Wkly 2019; 149: w20149.

20.

Setoguchi

Stevenson

Schneeweiss

Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007; 154: 260–266.

21.

Laribi

Aouba

Nikolaou

, et al. Trends in death attributed to heart failure over the past two decades in Europe. European Journal of Heart Failure 2012; 14: 234–239.

22.

Skorstengaard

Neergaard

Andreassen

, et al. Preferred Place of care and death in terminally ill patients with lung and heart disease compared to cancer patients. J Palliat Med 2017; 20: 1217–1224.

23.

Robinson

Gott

Gardiner

, et al. The ‘problematisation’ of palliative care in hospital: an exploratory review of international palliative care policy in five countries. BMC Palliative Care 2016; 15: 64.

24.

Sobanski

Alt-Epping

Currow

, et al. Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement. Cardiovasc Res 2020; 116: 12–27.

25.

Crispo

Davgun

Lucas

, et al. Palliative care consultation in patients admitted with Heart Failure (S728). J Pain Symptom Manag 2018; 55: 671.

26.

Jaarsma

Beattie

Ryder

, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11: 433–443.

27.

Kalter-Leibovici

Freimark

Freedman

, et al. Disease management in the treatment of patients with chronic heart failure who have universal access to health care: a randomized controlled trial. BMC Med 2017; 15: 90.

28.

Kronman

Ash

Freund

, et al. Can primary care visits reduce hospital utilization among medicare beneficiaries at the end of life? J Gen Intern Med 2008; 23: 1330–1335.

29.

Madan

Fida

Barman

, et al. Frailty assessment in advanced heart failure. J Card Fail 2016; 22: 840–844.

30.

Rogers

Patel

Mentz

, et al. Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial. J Am Coll Cardiol 2017; 70: 331–341.

31.

Unroe

Greiner

Johnson

, et al. Racial differences in hospice use and patterns of care after enrollment in hospice among Medicare beneficiaries with heart failure. Am Heart J 2012; 163: 987–993.e983.

32.

Kmet

Lee

Standard quality assessment criteria for evaluating primary research papers from a variety of fields. HTA Initiative 2004; 2. https://era.library.ualberta.ca/items/48b9b989-c221-4df6-9e35-af782082280e/download/a1cffdde-243e-41c3-be98-885f6d4dcb29 (accessed September 13th, 2022).

33.

Bone

Evans

Etkind

, et al. Factors associated with older people’s emergency department attendance towards the end of life: a systematic review. Eur J Public Health 2019; 29: 67–74.

34.

Henson

Gao

Higginson

, et al. Emergency department attendance by patients with cancer in their last month of life: a systematic review and meta-analysis. J Clin Oncol 2015; 33: 370–376.

35.

Gomes

Higginson

IJ.

Factors influencing death at home in terminally ill patients with cancer: systematic review. BMJ 2006; 332: 515–521.

36.

Pattenden

Mason

Lewin

RJ.

Collaborative palliative care for advanced heart failure: outcomes and costs from the ‘Better Together’ pilot study. BMJ Support Palliat Care 2013; 3: 69–76.

37.

Mentz

O’Connor

Granger

, et al. Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. Am Heart J 2018; 204: 202–204.

38.

Kheirbek

Alemi

Wojtusiak

, et al. Impact of hospice and palliative care service utilization on all-cause 30-day readmission rate for older adults hospitalized with heart failure. Am J Hosp Palliat Med 2019; 36: 623–629.

39.

Reed

Dunlap

, et al. In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). Am J Cardiol 2012; 110: 1150–1155.

40.

Warraich

DeVore

, et al. Trends in hospice discharge and relative outcomes among Medicare patients in the get with the Guidelines-Heart Failure Registry. JAMA Cardiol 2018; 3: 917–926.

41.

Russell

Baik

Jordan

, et al. Factors associated with live discharge of heart failure patients from hospice: a multimethod study. JACC Heart Fail 2019; 7: 550–557.

42.

Dunlay

Redfield

Jiang

, et al. Care in the last year of life for community patients with heart failure. Circ Heart Fail 2015; 8: 489–496.

43.

Ahmed

Mujib

Desai

, et al. Outcomes in younger and older adults with chronic advanced systolic heart failure: a propensity-matched study. Int J Cardiol 2012; 154: 128–133.

44.

Wiskar

Celi

Walley

, et al. Inpatient palliative care referral and 9-month hospital readmission in patients with congestive heart failure: a linked nationwide analysis. Intern Med J 2017; 282: 445–451.

45.

Petrie

Voors

van Veldhuisen

DJ.

Low pulse pressure is an independent predictor of mortality and morbidity in non ischaemic, but not in ischaemic advanced heart failure patients. Int J Cardiol 2009; 131: 336–344.

46.

Lam

Carson

Anand

, et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2012; 5: 571–578.

47.

Boman

Olofsson

Bergman

A-CR

, et al. Anaemia, but not iron deficiency, is associated with clinical symptoms and quality of life in patients with severe heart failure and palliative home care: a substudy of the PREFER trial. Eur J Intern Med 2017; 46: 35–40.

48.

Van Spall

HGC

Hill

, et al. P3519Sex-based disparities in end of life care among patients with heart failure. Eur Heart J 2019; 40(Suppl_1): 2129.

49.

MacKenzie

Hanlon

Health-care utilization after hospice enrollment in patients with heart failure and cancer. Am J Hospice Palliative Care 2018; 35: 229–235.

50.

Blecker

Herbert

Brancati

FL.

Comorbid diabetes and end-of-life expenditures among Medicare beneficiaries with heart failure. J Card Fail 2012; 18: 41–46.

51.

Domanski

Krause-Steinrauf

Deedwania

, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003; 42: 914–922.

52.

Bernacki

McDermott

Engelberg

, et al. Advance Care Planning and intensity of care at the end of life for adults with chronic kidney disease and congestive heart failure (RP302). J Pain Symptom Manag 2020; 60(1): 200–201.

53.

Gheorghiade

Flaherty

Fonarow

, et al. Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure. Int J Cardiol 2011; 151: 69–75.

54.

Ahmed

Aronow

Criqui

, et al. Effects of peripheral arterial disease on outcomes in advanced chronic systolic heart failure a propensity-matched study. Circ Heart Fail 2010; 3: 118–124.

55.

Ahmed

White

Ekundayo

, et al. A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. Eur Heart J 2009; 30: 2029–2037.

56.

Desai

Banach

Ahmed

, et al. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (Insights from the BEST trial). Am J Cardiol 2010; 106: 221–227.

57.

Böhm

Perez

A-C

Jhund

, et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail 2014; 16: 778–787.

58.

Haass

Kitzman

Anand

, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324–331.

59.

Shah

Qian

Di Tullio

, et al. Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction. Eur J Clin Invest 2019; 49: e13092.

60.

Di Giulio

. Should patients perception of health status be integrated in the prognostic assessment of heart failure patients? A prospective study. Qual Life Res 2014; 23: 49–56.

61.

Russell

Diamond

Lauder

, et al. Frequency and risk factors for live discharge from Hospice. J Am Geriatr Soc 2017; 65: 1726–1732.

62.

Shah

Hasselblad

Gheorghiade

, et al. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol 2001; 88: 987–993.

63.

Kristensen

Jhund

Køber

, et al. Relative Importance of history of heart failure hospitalization and N-terminal Pro-B-Type natriuretic peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2015; 3: 478–486.

64.

Kristensen

Mogensen

Jhund

, et al. N-Terminal Pro-B-type natriuretic peptide levels for risk prediction in patients with heart failure and preserved ejection fraction according to atrial fibrillation status. Circ Heart Fail 2019; 12: e005766.

65.

Miller

Hartman

Grill

, et al. Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clin Chem 2009; 55: 78–84.

66.

Tsimploulis

Weerakoon

Valentova

, et al. Baseline hypokalemia and long-term outcomes in ambulatory patients with heart failure with reduced ejection fraction (HFrEF) and New York heart association class III-IV: a propensity-matched study of beta-blocker evaluation of survival trial (BEST). J Card Fail 2016; 22: S87.

67.

Blecker

Anderson

Herbert

, et al. Hospice care and resource utilization in Medicare beneficiaries with heart failure. Med Care 2011; 49: 985–991.

68.

Brian Cassel

Kerr

McClish

, et al. Effect of a home-based palliative care program on healthcare use and costs. J Am Geriatr Soc 2016; 64: 2288–2295.

69.

Kheirbek

Fletcher

Bakitas

, et al. Discharge hospice referral and lower 30-day all-cause readmission in Medicare beneficiaries hospitalized for heart failure. Circ Heart Fail 2015; 8: 733–740.

70.

Brännström

Boman

Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study. Eur J Heart Fail 2014; 16: 1142–1151.

71.

Gelfman

Barrón

Moore

, et al. Predictors of hospice enrollment for patients with advanced heart failure and effects on health care use. JACC Heart Fail 2018; 6: 780–789.

72.

Lipinski

Eagles

Fischer

, et al. Heart failure and palliative care in the emergency department. Emerg Med J 2018; 35: 726–729.

73.

Yim

Barrón

Moore

, et al. Hospice enrollment in patients with advanced heart failure decreases acute medical service utilization. Circ Heart Fail 2017; 10: e003335.

74.

Wong

Lee

, et al. Effects of a transitional palliative care model on patients with end-stage heart failure: a randomised controlled trial. Heart 2016; 102: 1100–1108.

75.

Lycett

Schaefer

Bernacki

RE.

Inpatient palliative care consultation for patients with advanced heart failure. J Am Geriatr Soc 2010; 58: S165.

76.

Chuang

Kim

Blank

, et al. 30-Day readmission rates in patients admitted for heart failure exacerbation with and without palliative care consultation: a retrospective cohort study. J Palliat Med 2017; 20: 163–169.

77.

Jones

Sin

M-K

Hage

, et al. Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the veterans affairs versus other hospitals: insights from the beta-blocker evaluation of Survival Trial (BEST). Circ Heart Fail 2015; 8: 17–24.

78.

Ashana

Chen

Agiro

, et al. Advance care planning claims and health care utilization among seriously ill patients near the end of life. JAMA Network Open 2019; 2: e1914471.

79.

Wong

Tan

Seow

, et al. Home-based advance care programme is effective in reducing hospitalisations of advanced heart failure patients: a clinical and healthcare cost study. Ann Acad Med Singap 2013; 42: 466–471.

80.

Curtis

Greiner

Unroe

, et al. End-of-life care in heart failure: differences between the U.S. and Canada. Circ Cardiovasc Qual Outcomes 2011; 4 (suppl_1): AP112.

81.

Kaul

McAlister

Ezekowitz

, et al. Resource use in the last 6 months of life among patients with heart failure in Canada. Arch Intern Med 2011; 171: 211–217.

82.

Kristensen

Køber

Jhund

, et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation 2015; 131: 43–53.

83.

Diop

Rudolph

Zimmerman

, et al. Palliative care interventions for patients with heart failure: A systematic review and meta-analysis. J Palliat Med 2017; 20: 84–92.

84.

Chen

Jin

, et al. Effect of palliative care for patients with heart failure. Int Heart J 2018; 59: 503–509.

85.

Sahlollbey

Lee

CKS

Shirin

, et al. The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials. Eur J Heart Fail 2020; 22: 2340–2346.

86.

Moens

Higginson

Harding

Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight Non-Cancer conditions? A systematic review. J Pain Symptom Manag 2014; 48: 660–677.

87.

Billings

Bernacki

Strategic targeting of advance care planning interventions: the Goldilocks phenomenon. JAMA Intern Med 2014; 174: 620–624.

88.

Ponikowski

Voors

Anker

, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37: 2129–2200.

89.

Crespo-Leiro

Metra

Lund

, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20: 1505–1535.

90.

McDonagh

Metra

Adamo

, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599–3726.

91.

Zhou

Mao

Palliative care in heart failure : A meta-analysis of randomized controlled trials. Herz 2019; 44: 440–444.

92.

Thomas

O’Leary

Fried

TR.

Understanding their options: determinants of hospice discussion for older persons with advanced illness. J Gen Intern Med 2009; 24: 923–928.

93.

Cheung

Schaefer

May

, et al. Enrollment and events of hospice patients with heart failure vs. cancer. J Pain Symptom Manag 2013; 45: 552–560.

94.

Kavalieratos

Mitchell

Carey

, et al. Not the ‘grim reaper service’: an assessment of provider knowledge, attitudes, and perceptions regarding palliative care referral barriers in heart failure. J Am Heart Assoc 2014; 3: e000544.

95.

Romanò

Barriers to early utilization of palliative care in heart failure: a narrative review. Healthcare 2020; 8: 36.

96.

Ziaeian

Kominski

Ong

, et al. National differences in trends for heart failure hospitalizations by sex and race/ethnicity. Circ Cardiovasc Qual Outcomes 2017; 10: e003552.

97.

Husaini

Levine

Norris

, et al. Heart failure hospitalization by race/ethnicity, gender and age in california: implications for prevention. Ethn Dis 2016; 26: 345–354.

98.

Schonwetter

Clark

Leedy

, et al. Predicting emergency room visits and hospitalizations among hospice patients with cardiac disease. J Palliat Med 2008; 11: 1142–1150.

99.

Henson

Higginson

Gao

What factors influence emergency department visits by patients with cancer at the end of life? Analysis of a 124,030 patient cohort. Palliat Med 2018; 32: 426–438.

100.

Henson

Gao

Higginson

, et al. Emergency department attendance by patients with cancer in the last month of life: a systematic review and meta-analysis. Lancet 2015; 385(Suppl 1): S41.

101.

Rizzuto

Aldridge

MD.

Racial disparities in hospice outcomes: a race or hospice-level effect?

J Am Geriatr Soc 2018; 66: 407–413.

102.

Johnson

KS.

Racial and ethnic disparities in palliative care. J Palliat Med 2013; 16: 1329–1334.

103.

Hussain

Koffman

Bajwah

Invited editorials. Palliat Med 2021; 35: 810–813.

104.

Quest

Periyakoil

Quill

, et al. Racial equity in palliative care. J Pain Symptom Manag 2021; 61: 435–437.

105.

Givens

Tjia

Zhou

, et al. Racial and ethnic differences in hospice use among patients with heart failure. Arch Intern Med 2010; 170: 427–432.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.77 MB

0.15 MB